Search results

  • Full text

  • Document type

    • Publication year

  • Organisation

Results: 66
Number of items: 66
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 1 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673812.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 13 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673803.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P., & Van Kampen, A. H. C. (2020). Additional file 8 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673833.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 10 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673794.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 2 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673815.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 14 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673806.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 3 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673818.v1
  • Mandemaker, I. K., Zhou, D., Bruens, S. T., Dekkers, D. H., Verschure, P. J., Edupuganti, R. R., Meshorer, E., Demmers, J. A. A., & Marteijn, J. A. (2020). Histone H1 eviction by the histone chaperone SET reduces cell survival following DNA damage. Journal of Cell Science, 133, Article jcs235473. https://doi.org/10.1242/jcs.235473
  • Open Access
    Borgoni, S., Sofyali, E., Soleimani, M., Wilhelm, H., Müller-Decker, K., Will, R., Noronha, A., Beumers, L., Verschure, P. J., Yarden, Y., Magnani, L., van Kampen, A. H. C., Moerland, P. D., & Wiemann, S. (2020). Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer. Cancers, 12(10), Article 2918. https://doi.org/10.3390/cancers12102918
  • Open Access
    Soleimani Dodaran, M., Borgoni, S., Sofyali, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & van Kampen, A. H. C. (2020). Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2-breast cancer. BMC Cancer, 20, Article 676. https://doi.org/10.1186/s12885-020-07100-z
Page 2 of 7